Abstract: Both $^{68}$Ga-PSMA-11 PET-CT and multiparametric MRI (mpMRI) demonstrate significant value for lymph node (LN) staging in patients with intermediate- to high-risk prostate cancer (PCa) undergoing radical prostatectomy with pelvic lymph node dissection. However, despite the excellent performance of $^{68}$Ga-PSMA-11 PET-CT, it cannot replace mpMRI, which remains essential for preoperative evaluation.
Introduction
Accurate staging of pelvic lymph nodes is a critical component of surgical planning and prognosis for patients with intermediate- to high-risk prostate cancer. Traditionally, clinical staging relied on CT or standard MRI, which identify suspicious nodes based primarily on size (typically a short-axis diameter >10mm). This morphological approach is limited, as small nodes may contain micrometastases and enlarged nodes may be reactive rather than malignant.
Two advanced imaging modalities have emerged to address these limitations: multiparametric MRI (mpMRI), which provides high anatomical detail and functional data (diffusion and perfusion), and $^{68}$Ga-PSMA-11 PET-CT, a molecular imaging technique that targets the Prostate-Specific Membrane Antigen (PSMA) overexpressed in prostate cancer cells.
Methods and Materials
This retrospective study evaluated 42 consecutive patients with intermediate-to-high-risk PCa who underwent both 3.0-T mpMRI and $^{68}$Ga-PSMA-11 PET-CT prior to robot-assisted radical prostatectomy (RARP) and pelvic lymph node dissection (PLND).
The study utilized histopathology as the gold standard. A total of 621 resected lymph nodes were mapped and examined, with 51 nodes confirmed as metastatic. The diagnostic performance of both imaging modalities was then compared against these pathological results on both a patient-based and region-based level.
Key Insights
Molecular vs. Morphological Correlation
The study found that the metabolic activity of the primary tumor, represented by the maximum standardized uptake value (SUV$_{max}$) on PET, was a significant predictor of nodal spread. Patients with lymph node metastases had a significantly higher primary tumor SUV$_{max}$ (13.10) compared to those without (7.22).
Diagnostic Thresholds
Researchers identified an optimal SUV$_{max}$ threshold of >3.25 for identifying suspicious lymph nodes. Using this cutoff, PET-CT achieved a specificity of 99.8%. Both modalities proved effective at identifying metastases in nodes that did not meet traditional size-based criteria for malignancy.
Results
The quantitative performance metrics for both modalities were remarkably high and statistically comparable at the patient level:
| Metric (Patient-based) | $^{68}$Ga-PSMA-11 PET-CT | mpMRI |
|---|---|---|
| Sensitivity | 93.33% | 93.33% |
| Specificity | 96.30% | 96.30% |
| Positive Predictive Value (PPV) | 93.33% | 87.50% |
| Negative Predictive Value (NPV) | 96.30% | 96.15% |
In region-based analysis, PET-CT showed a slight edge in specificity (99.65% vs. 99.47%), indicating a marginally lower rate of false positives compared to mpMRI.
Discussion and Conclusion
While $^{68}$Ga-PSMA-11 PET-CT is a powerful molecular tool for detecting metastatic spread, the study emphasizes that it serves as a complement to, rather than a replacement for, mpMRI. mpMRI remains superior for evaluating the local extent of the primary tumor, such as extracapsular extension and seminal vesicle invasion, which are vital for surgical precision.
The findings suggest that integrating the molecular insights of PSMA PET-CT with the structural detail of mpMRI provides the most comprehensive preoperative staging for high-risk prostate cancer patients. Future prospective, multi-center trials are needed to further refine how these technologies are best utilized in combination.
Summary updated